Mark L. Gonzalgo, M.D., Ph.D.
Academic Appointments
- Associate Professor - Med Center Line, Urology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Urology Clinic 875 Blake Wilbur Dr MC 5826 Stanford, CA 94305 Tel Work (650) 725-5544 Fax (650) 723-0765
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Urologic Oncology
- Prostate Cancer - Robotic Prostatectomy
- Bladder Cancer - Robotic Cystectomy
- Urologic Oncology - Prostate, Bladder, Kidney, Testicular Cancer
- Urology
Administrative Appointments
- Director, Robotic-Assisted Urologic Cancer Surgery, Stanford University (2009 - present)
- Physician Leader, Urologic Cancer Care Program, Stanford Cancer Center (2012 - present)
Honors and Awards
- Outstanding Reviewer Award (Prostate Cancer), The Journal of Urology, American Urological Association (2010)
- Career Development Award, Prostate Cancer Foundation (2006)
- Gerald P. Murphy Scholar, American Urological Association (2005)
- Alpha Omega Alpha, Johns Hopkins University (2005)
- First Place, Basic Sciences, AUA Mid-Atlantic Resident Prize Essay Competition (2003)
- Irving I. Lasky Award for Most Outstanding Research, USC Keck School of Medicine (1999)
Professional Education
| Residency: | John Hopkins Hospital MD (12/31/2004) |
| Board Certification: | Urology, American Board of Urology (2008) |
| Fellowship: | Memorial Sloan-Kettering Cancer Center, NY USA (06/30/2006) |
| Residency: | John Hopkins Hospital MD (06/30/2001) |
| Medical Education: | USC Keck School of Medicine CA (05/14/1999) |
| M.D.: | University of Southern California, Medicine (1999) |
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
My laboratory is focused on studying the role of DNA methylation in prostate and bladder cancer. Certain genes and their downstream targets may be useful molecular markers for disease detection and prognostication. We are interested in utilizing methylation markers to detect abnormal changes in serum and urine. Clinical Focus: Prostate Cancer - Robotic Prostatectomy; Bladder Cancer - Robotic Cystectomy; Urologic Oncology - Prostate, Bladder, Kidney, Testicular Cancer.
Clinical Trials
- Recruiting Quality of Life Following Radical Prostatectomy
- Recruiting Prostate Active Surveillance Study
- Not Recruiting Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer
- Not Recruiting Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study
- Recruiting Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial
Publications
- Stage I testicular seminoma: a SEER analysis of contemporary adjuvant radiotherapy trends. J Urol. 2013
- Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol. 2012 Jul-Aug; (4): 428-33
- Characteristics of positive surgical margins in robotic-assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center. Hum Pathol. 2012; (2): 254-60
- Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int. 2012; (6): 898-905
- Learning from our patients: complications and the future of radical cystectomy for bladder cancer. J Urol. 2012; (6): 2018
- Editorial comment. J Urol. 2011; (1): 35-6
Help